What Are Peptides? A Plain-English Introduction.

The one-sentence definition

A peptide is a short chain of amino acids linked by peptide bonds. "Short" is the operative word. Most scientists use a soft cutoff of around 50 amino acids — above that, the same molecule is usually called a protein; below it, a peptide. Two amino acids joined together form a dipeptide, three a tripeptide, up to a few dozen an oligopeptide, and longer strings a polypeptide.^[1]

The molecules sold as "research peptides" almost all fall between 3 and 40 amino acids. GHK-Cu is 3 amino acids. BPC-157 is 15. Retatrutide is a modified chain of 39 residues. Insulin — which is technically a peptide hormone — sits at 51 residues and is usually called a protein. The boundary is fuzzy on purpose.

Peptides vs. proteins vs. amino acids

Think of the three categories as the same thing at three scales:

The reason the boundary matters isn't chemistry — peptides and proteins share the same backbone — it's behaviour. Short peptides can slip through barriers proteins can't, they can often be manufactured synthetically on a benchtop, and they tend to have shorter half-lives, which is sometimes a feature and sometimes a bug.

How peptides are made

There are two production routes:

• Biologically. Your ribosomes assemble peptides all day long. Hormones like glucagon, growth hormone-releasing hormone (GHRH) and vasopressin are endogenous peptides. The molecules we buy as research compounds are often analogs — synthetic cousins — of these natural signalling molecules.
• Synthetically. Since the 1963 Merrifield method, chemists have been able to build peptides one amino acid at a time on a solid resin — solid-phase peptide synthesis (SPPS).^[2] That's why almost every research peptide on the market can be made at arbitrary purity in a GMP lab. HPLC (high-performance liquid chromatography) is then used to verify the purity, which is why you see ≥99% HPLC on every reputable vial.

When a peptide is delivered, it's typically supplied as a white lyophilized powder (freeze-dried). Reconstitution — mixing with bacteriostatic water — happens at the point of use, because dissolved peptides degrade quickly.

Why peptides matter biologically

Peptides are signalling molecules. They fit into receptors in the same way a key fits a lock. Because they're short and often specific to one receptor, a peptide drug can in theory produce a clean, targeted effect — the holy grail in drug design, where "clean" means few off-target side effects.

Consider the stakes:

• Insulin (a peptide) rewrote what was possible for type 1 diabetes in 1922.
• Oxytocin (9 amino acids) drives labour and bonding.
• GLP-1 analogs (semaglutide, tirzepatide, retatrutide) are reshaping obesity medicine this decade.
• ACTH, vasopressin, calcitonin, somatostatin, atrial natriuretic peptide — all peptide hormones with clinical use.

So when you see a peptide discussed in the research literature — BPC-157 for tissue repair, TB-500 for angiogenesis, GHK-Cu for skin remodelling — the theoretical premise is always the same: a short, specific molecule that nudges a receptor or signalling pathway the body already uses.

From research compound to approved drug

Drug approval moves slowly on purpose. A peptide identified in basic research has to pass through:

1. In vitro (cell culture) and in vivo (animal) studies — to establish mechanism and toxicity.
2. Phase I human trials — small safety studies.
3. Phase II — efficacy at scale.
4. Phase III — large randomised controlled trials.
5. Regulatory review (FDA, EMA, CDSCO in India).

Many research peptides — BPC-157, TB-500, MOTS-C, Ipamorelin, CJC-1295 — have strong animal data but have not completed human trials sufficient for drug approval in any major market. They sit in a well-defined legal category: research chemicals, legal to manufacture, possess and study in a laboratory, but not legal to market or prescribe as medicine.

A few — Tesamorelin, Semaglutide, Liraglutide, Retatrutide (in late-stage trials) — have crossed that line and exist as approved or pending drugs. The distinction matters legally and matters scientifically: a peptide with an FDA label comes with a data package of tens of thousands of patient-years. A peptide with 40 rat studies comes with a smaller one.

The classes you'll encounter

The peptides most researchers ask about fall into roughly six functional classes. We cover the full taxonomy in the companion article, Types of Peptides: A Map of the Six Main Classes. A quick preview:

• Healing / repair peptides — BPC-157, TB-500, GHK-Cu
• Growth-hormone secretagogues — CJC-1295, Ipamorelin, Sermorelin, Tesamorelin
• Metabolic / obesity peptides — Semaglutide, Tirzepatide, Retatrutide
• Mitochondrial peptides — MOTS-C, SS-31
• Cognitive / neurogenic peptides — Semax, Selank, Cerebrolysin
• Cosmetic peptides — GHK-Cu (overlaps), Matrixyl, Argireline

Regulation in India and globally

India regulates drugs under the Drugs and Cosmetics Act, 1940 and associated rules administered by CDSCO. Peptides in the research-chemical category are legal to import, possess and use for laboratory research. They are not approved for human therapeutic use unless specifically listed (Tesamorelin, for example, is FDA-approved but is not approved in India for general therapeutic supply as of this writing).

Globally, the picture is similar. The US FDA permits sale of unapproved compounds as "research use only" (RUO) provided they aren't marketed or labelled for human consumption. The UK, EU and Australia operate comparable frameworks. What differs is enforcement posture and how strictly the RUO line is policed.

The practical takeaway for the reader: a research peptide is a legitimate tool in a scientific setting. It is not a substitute for a prescription medication, and no responsible supplier frames it that way.

The honest limitations

Three things to hold in mind whenever you read about a research peptide:

1. Animal data doesn't always translate. BPC-157 has remarkable rat data for tendon and gut healing. The human evidence is limited to small case series and off-label anecdote. Enthusiasm should be bounded by that.
2. "Reported dose ranges" in the literature are not prescriptions. When a paper reports that a compound was dosed at 250 mcg/kg in rats, that's a study parameter, not a recommendation for you. Scaling between species is non-trivial and the human dosing ranges quoted for many research peptides rest on very thin evidence.
3. Purity, identity and stability matter. A peptide is only what the certificate of analysis (COA) says it is. Degradation, contamination, or mis-identification are the failure modes nobody talks about loudly enough. Reputable sources, verified lot numbers, cold-chain handling — these aren't nice-to-haves, they're the whole game.